Read the original post: PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
Read the original post: PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
The rest is here: 22nd Century Group (XXII) Regains Compliance with Nasdaq Listing Standards
Read the rest here: 23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
See the original post: SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Originally posted here: Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
Originally posted here: Guerbet: First-half 2023 revenue
See more here: Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
Go here to read the rest: Sagimet Biosciences Announces Leadership Changes
View post: ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit...
Recent Comments